Puma Biotechnology

Puma Biotechnology acquires and develops innovative products for the treatment of various forms of cancer. Its focus on in-licensing innovative drug candidates that are undergoing or have already completed initial clinical testing for the treatment of various forms of cancer and then seek to further develop these drug candidates for commercial use.

Company Growth (employees)
Type
Public
HQ
Los Angeles, US
Founded
2010
Size (employees)
160 (est)
Puma Biotechnology was founded in 2010 and is headquartered in Los Angeles, US

Key People at Puma Biotechnology

Alan H. Auerbach

Alan H. Auerbach

Chief Executive Officer, President
Troy Wilson

Troy Wilson

Member of the Board of Directors

Puma Biotechnology Office Locations

Puma Biotechnology has offices in Los Angeles and San Francisco
Los Angeles, US (HQ)
10880 Wilshire Blvd

Puma Biotechnology Data and Metrics

Puma Biotechnology Financial Metrics

USD

Net income (Q1, 2017)

(72.9 m)

EBIT (Q1, 2017)

(73.2 m)

Market capitalization (22-Aug-2017)

3 b

Cash (31-Mar-2017)

105.1 m
Puma Biotechnology's current market capitalization is $3 b.
USDFY, 2013FY, 2016

R&D expense

222.8 m

General and administrative expense

53.8 m

Operating expense total

276.6 m

EBIT

(139.4 m)(276.6 m)

Interest income

958 k

Net Income

(139.3 m)(276 m)
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

R&D expense

35 m32.1 m44.7 m59.4 m51.9 m60.2 m54.2 m52 m54.8 m

General and administrative expense

3.9 m3.9 m7.9 m5.5 m8.8 m11 m12.3 m14 m18.4 m

Operating expense total

38.9 m36 m52.6 m64.9 m60.7 m71.2 m66.5 m66 m73.2 m

EBIT

(38.9 m)(36 m)(52.6 m)(64.9 m)(60.7 m)(71.2 m)(66.5 m)(66 m)(73.2 m)

Interest income

66 k111 k123 k213 k318 k282 k260 k214 k350 k

Net Income

(38.8 m)(35.8 m)(52.5 m)(64.7 m)(60.4 m)(71 m)(66.6 m)(65.8 m)(72.9 m)
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

43 m38.5 m31.6 m194.5 m

Current Assets

96.4 m149.4 m223.5 m236.5 m

PP&E

1.7 m2.2 m2.4 m5.2 m

Total Assets

104.4 m162.8 m239.8 m252.8 m

Accounts Payable

10.7 m15 m17.8 m20 m

Current Liabilities

19.3 m44.4 m32.4 m37.5 m

Total Liabilities

43 m

Additional Paid-in Capital

223.2 m399.2 m726.7 m1 b

Retained Earnings

(281.2 m)(520.5 m)(796.5 m)

Total Equity

84 m117 m206 m209.8 m

Financial Leverage

1.2 x1.4 x1.2 x1.2 x
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Cash

55.4 m28.3 m155.5 m59.8 m23.6 m78.2 m57.8 m52.5 m105.1 m

Current Assets

183.6 m160.1 m316.7 m287.8 m254.7 m189.4 m153.7 m117.4 m204.6 m

PP&E

1.9 m1.9 m2.4 m2.6 m2.5 m2.2 m5.2 m5.2 m5 m

Total Assets

196.1 m172.1 m331.9 m302.4 m271.6 m205.2 m170.9 m134 m216.6 m

Accounts Payable

18.8 m18.4 m12.6 m10.4 m9.8 m24.8 m24.6 m20.9 m24 m

Current Liabilities

27.9 m29.4 m26.1 m26.1 m25.3 m38.9 m39 m37.6 m43.7 m

Additional Paid-in Capital

365 m375.5 m638.1 m673.5 m703.7 m756.4 m785.1 m815 m1 b

Retained Earnings

(333.7 m)(398.4 m)(458.8 m)(591.5 m)(658.1 m)(723.9 m)(869.4 m)

Total Equity

167 m141.6 m304.3 m274.8 m244.8 m164.9 m127.1 m91.1 m167.4 m

Financial Leverage

1.2 x1.2 x1.1 x1.1 x1.1 x1.2 x1.3 x1.5 x1.3 x
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(54.7 m)(142 m)(239.3 m)(276 m)

Depreciation and Amortization

423 k627 k776 k1.1 m

Accounts Payable

10.2 m4.3 m2.8 m2.2 m

Cash From Operating Activities

(55 m)(77.2 m)(154.5 m)(141.7 m)

Purchases of PP&E

(624 k)(1.1 m)(1 m)(4.3 m)

Cash From Investing Activities

(41.5 m)(63.3 m)(85.9 m)142.2 m

Cash From Financing Activities

2.2 m136 m233.4 m162.4 m
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(38.8 m)(35.8 m)(52.5 m)(64.7 m)(60.4 m)(71 m)(66.6 m)(65.8 m)(72.9 m)

Accounts Payable

18.8 m18.4 m12.6 m10.4 m9.8 m24.8 m24.6 m20.9 m24 m
Y, 2017

Financial Leverage

1.3 x

Puma Biotechnology Market Value History

Traffic Overview of Puma Biotechnology

Puma Biotechnology News and Updates

Former Puma Biotechnology exec is accused of making $1.2 million from insider trading

The Securities and Exchange Commission charged Robert Gadimian, a former executive at Los Angeles’ Puma Biotechnology, with making nearly $1.2 million by illegally trading on confidential information about an experimental breast cancer drug. The agency said Thursday that Gadimian, who was Puma’s…

Puma Biotechnology Company Life and Culture

You may also be interested in